Albert Tzu-Ming Chuang

2 months ago | cmaj.ca | Daniel Tsai |Albert Tzu-Ming Chuang |Kuan-Hung Liu |Shih-Chieh Shao

Mineral and bone disorders (MBD) — characterized by hypocalcemia, hyperphosphatemia, and abnormalities in parathyroid hormone (PTH) and vitamin D metabolism — are observed in 50%–74% of patients with type 2 diabetes mellitus and chronic kidney disease (CKD).1,2 Regular monitoring of biochemical abnormalities and bone diseases in patients with CKD is suggested for early detection of developing CKD-MBD.3 The 2024 American Diabetes Association guideline recommends that adults with type 2...

Mar 4, 2024 | jamanetwork.com | Shih-Chieh Shao |Daniel Tsai |Albert Tzu-Ming Chuang |Jia-Chian Hu

Key PointsQuestion  Is the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors associated with reduced risk of anemia in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) stages 1 to 3? Findings  In this cohort study with 13 799 participants, initiation of SGLT2 inhibitors was associated with a 19% decrease in incident anemia risk compared with initiation of glucagon-like peptide-1 receptor agonists.